We are thrilled to announce that Tiba Biotech has been selected to join BLUE KNIGHT™, a joint initiative between Johnson & Johnson Innovation – JLABS (‘JLABS’) and the Biomedical Advanced Research and Development Authority (‘BARDA’). BARDA is within the Administration for Strategic Preparedness and Response (‘ASPR’), a part of the U.S. Department of Health and Human Services. This unique partnership aims to harness innovation to combat future known and unknown health threats.

This is a unique opportunity to apply our next-generation nucleic acid delivery technology to develop new products that can guard against and respond to public health threats.

Tiba Biotech is leveraging its cutting-edge RNABL™ technology to develop next-generation RNA vaccines and therapeutics. Our proprietary platform, based on dendrimer nanoparticles initially pioneered at the Massachusetts Institute of Technology and the Whitehead Institute, can deliver large nucleic acid payloads without the side effects of traditional lipid nanoparticles.

“We are excited to be named a Blue Knight company,” said Karl Ruping, CEO of Tiba Biotech. “This is a unique opportunity to apply our next-generation nucleic acid delivery technology to develop new products that can guard against and respond to public health threats.”

The Blue Knight collaboration is dedicated to anticipating global health security risks, activating the global innovation community, and amplifying scientific and technology advancements to response to a rapidly evolving global health environment.

Through Blue Knight, Tiba Biotech will become a virtual company within JLABS, a premier life science incubator program with a global network of open innovation ecosystems. This will provide us with invaluable resources and support to bring our healthcare solutions to patients faster.

For more information on the Blue Knight program see The Blue Knight Story.